Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

It's 1984. 

Peter Molloy is a microbiologist and product manager at F.H. Faulding & Co. in Adelaide (one of Australia's great old pharmaceutical companies), and he has an idea.

The idea is simple. 

Betadine has been on the market since 1971. 

The active ingredient kills bacteria and viruses on contact. 

Every Australian household has a bottle of the dark amber liquid somewhere in the back of a bathroom cabinet. We know it works.

Molloy's insight… What kills pathogens on your skin should kill them in your throat.

The American company behind Betadine, the now notorious Purdue Pharma, didn't see it that way. 

They saw Betadine as a hospital antiseptic, a surgical scrub, not a sore throat gargle. 

Molloy pushed it to market anyway. That was before the TGA existed.

Betadine Sore Throat Gargle became Australia's best-selling over-the-counter sore-throat treatment. 

It's been on pharmacy shelves for forty years and sells around two million units a year. 

Never got approved in the United States thanks to Purdue Pharma, but in Australia, it's a household name.

Now fast-forward to 2012.

Molloy is more experienced, and he has another idea. 

If the active ingredient in Betadine kills viruses in the throat, it should kill them in the nose too. 

Same logic. Same ingredient. Same person.

Same result?

Not even close.

Not remotely.

Firebrick Pharma (ASX: FRE) was co-founded by Peter Molloy and Stephen Goodall in 2012. 

The vision was to do for the nasal cavity what Betadine had done for the throat: develop a safe, effective, broad-spectrum antimicrobial nasal spray and get it into pharmacies worldwide.

The product, Nasodine Nasal Spray, is a 0.5% PVP-I formulation. 

By 2018, the product was fully developed, and the Phase 1 data showed no meaningful iodine absorption, no thyroid effects, and good tolerability at four doses a day for five days. 

Lab studies showed Nasodine killed every known respiratory virus, including rhinoviruses, coronaviruses, RSV, and adenoviruses, within 60 seconds of contact. 

The WHO has had PVP-I (the active ingredient in Betadine) on its Essential Medicines list for decades.

Molloy's goal was to obtain quick OTC approval in Australia as a nasal sanitiser or antiseptic. 

Something that sidesteps the full drug approval process, the same way Betadine had.

The TGA had other plans.

Here's the thing about Betadine in Australia. The hospital antiseptic was launched in 1971, and the gargle in 1984. 

The TGA didn't exist until 1991. 

When the TGA came into force, Betadine was already a 20-year-old brand with a decades-long safety record, and the gargle was well established in Australian pharmacies. 

The gargle was grandfathered onto the Australian Register of Therapeutic Goods without having to prove its efficacy by modern standards. 

The TGA explicitly acknowledges this: grandfathered products aren't eligible to carry the "TGA assessed" claim precisely because they never underwent assessment.

Nasodine in 2020? No such luck.

The TGA reviewed the application and determined that this product makes therapeutic claims (treating the common cold) and therefore needs to be evaluated as a drug. 

Not an antiseptic. 

Which means Phase 3 clinical trial data. 

Which means proving, in a rigorous randomised controlled trial, that Nasodine actually works.

This is where the story starts to get complicated.

Running a clinical trial for the common cold is hard.

Not because colds are severe, but rather because they are not.

Think about it from first principles. 

You need to:

A cold lasts 7–10 days, but viral load peaks in the first 24–48 hours. 

If your topical nasal spray works by killing the virus before it can replicate, you need to use it early. 

(This is what Firebrick’s first clinical trial showed)

By the time most patients notice their symptoms, drive to a trial site, get screened, and receive their first dose, they're already 36–48 hours in. 

The virus has already done most of its damage.

There's a subgroup in Firebrick's first Phase 3 trial, the "24S" group, which showed a 39.7% reduction in overall cold severity compared to placebo.

But only 29 of 260 enrolled patients made it in that quickly.

This is the recruitment window problem. 

Almost every antiviral that has ever been tested against the common cold has run into the same wall. 

So, while the smaller subgroup of patients who arrived early for the trial showed a reduction in overall cold severity, the TGA would not approve the product as a drug since it did not meet the primary endpoint.

This was in 2020.

Then COVID-19 arrives.

Getting a product to market quickly was important. 

There was a window of capital and attention that Nasodine could fill between.

But it was a short window.

Firebrick had a product sitting ready. GMP-manufactured. Phase 2 safety data. A founder who had spent three decades in the industry and had the networks to move fast.

Firbrick had a solution. 

But if they were late to market, they might not get another opportunity like this.

It all hinged on speed.

The TGA itself, as Molloy described it, did not want products on the market that might interfere with the vaccine rollout. 

Whatever the exact mechanism, administrative overload, vaccine-first prioritisation, or simply the structural reality that no one gets an OTC approval in the middle of a pandemic…

The window closed.

Meanwhile, in the United States, the FDA was sending warning letters to every company trying to sell a PVP-I nasal spray with any COVID-adjacent claim. 

Halodine. Viraldine. CofixRx. 

All received formal warnings in 2021–2022. 

The FDA's position…

These products are unapproved new drugs; the 1994 regulatory framework for OTC consumer antiseptics explicitly doesn't cover intranasal use; and any COVID-related claim without clinical trial data is unlawful.

The grey market got ugly. 

Companies were selling "COVID Killer" sprays on Amazon. 

The FDA crackdown that followed tainted the entire category, legitimate and illegitimate players alike.

Firebrick had real data, real GMP manufacturing, and a real product, but it didn't matter. 

The regulators weren’t having a bar of it.

The 24-month window of peak demand, January 2021 to December 2022, passed with Nasodine stuck in regulatory purgatory.

In January 2022, Firebrick listed on the ASX.

While the TGA had rejected the company’s application for approval, it needed funding to run a second Phase 3 trial incorporating all lessons learned from the first one.

A different primary endpoint and adjustments for the placebo group.

Five hundred subjects enrolled. It exceeded the target. Everything looked set up for redemption.

September 13, 2023. Results.

Disaster.

Not only did the trial fail its primary endpoint, but the placebo also outperformed Nasodine. 

All that the company could do was describe the results as "inexplicable."

This meant that the Australian regulatory pathway was effectively closed, and the appeal against the initial TGA decision was withdrawn.

But the company did not give up on the product.

It pivoted. From being a drug with therapeutic claims, to an antiseptic.

Now, the TGA did not allow this regulatory pathway, but other jurisdictions did.

Here's the thing about Nasodine's regulatory journey outside Australia.

In the United States, it's sold as a "nasal cleanser." Technically classified as a cosmetic.

No FDA approval required. 

In Singapore, the Health Sciences Authority explicitly states that topical antiseptics, products applied to skin or mucosal membranes to kill microorganisms, require no pre-market approval whatsoever. 

Nasodine launched at Guardian pharmacies in January 2025.

In Indonesia, the Ministry of Health approved Nasodine in July 2026 as an antiseptic within the "Household Health Supplies" category, the same broad category as hand sanitisers and disinfectants. 

In the Philippines, a registration dossier was accepted for review by the local FDA in January 2026. 

Approval expected in the second half of 2026. Local manufacturing has commenced through partner SV More Pharma Group.

(who actually took a $1.2M position in Firebrick in March last year)

So while the product is the same, the regulatory label varies by country.

The TGA wanted Nasodine positioned as a drug that treats the common cold. 

Other regulators were perfectly comfortable positioning it as an antiseptic that kills germs in the nasal passage. 

It's not that one is right and one is wrong; it's that the regulatory category determines the evidentiary requirement. 

One of the key lessons in the Firebrick story is that it chose the wrong market first.

If Molloy had taken Nasodine to Singapore first in 2018, he'd have had a launched commercial product before the TGA ever came into the picture. 

He might have had several other markets generating revenue by the time COVID arrived. 

The product might have been in enough pharmacies to capture even a fraction of the enormous pandemic-era demand for nasal protection products.

…but that's not how it played out.

Instead, the company spent the better part of a decade fighting a regulatory system it couldn't win.

Same ingredient. Different era. And a completely different set of rules.

Today, Firebrick sits at a market cap of $16M.

The company just raised $1.5M at 4.7 cents per share.

With a regulatory pathway, but limited markets, the goal is now to create a profitable enterprise from the Nasodine spray in the markets that work.

Molloy has done this before with Betadine.

He knows how to market the product, articulate the value proposition to pharmacies, and identify the right partners in each new jurisdiction.

The main risk for the business is clearly commercial execution risk.

How much can they sell?

How long will it take them to get there?

At what point does this turn into a profitable business?

Right now, the goal is to enter 10 markets over the next three years.

So far, Nasodine is sold in the US, Fiji, Indonesia, Singapore, and soon in Indonesia and the Philippines. 

At 1 million units sold per year, that’s breakeven.

There are some key lessons to take away from the Firebrick story.

FIRST: The category you compete in determines the evidence you need. 

The TGA's insistence on treating Nasodine as a drug rather than an antiseptic set Firebrick back years in regulatory burden.

SECOND: Choose your markets carefully. 

By targeting Australia first, Firebrick was starting behind the eight ball. 

An earlier launch in Singapore, or in a similarly permissive market, could have generated commercial proof and revenue before the TGA ever entered the picture.

THIRD: Timing and windows of opportunity are unforgiving.

COVID was a once-in-a-generation moment. 

Firebrick had the science, the manufacturing, and the credibility, but spent those 24 critical months stuck in regulatory purgatory.

FOURTH: Clinical trial design can doom a good product. 

The recruitment window for common cold trials is a structural problem.

If your product needs to be used within 24 hours, but patients don't enrol until 48 hours in, the trial is compromised before it starts.

So, how does Firebrick stack up today?

The addressable market has shifted from "the product that could have defined pandemic preparedness" to "a useful nasal antiseptic for everyday respiratory hygiene." 

That is an uphill battle for the company.

BUT, Peter Molloy has done it before.

He turned Betadine into a blockbuster product.

And there is a clear pathway for the company to get the product on shelves.

It’s just that the proof will be in the sales.

A big thank you to Peter Molloy for sharing the Firebrick story.

See you all tomorrow,

The Armchair Analyst.

Orthocell (ASX: OCC) secures approval for its Remplir™ nerve repair device across 51 U.S. Department of Defence hospitals and 170 VA medical centres. (OCC)

🪑 Nice deal.

Genetic Signatures (ASX: GSS) signs a 10-year supply agreement of various equipment and reagents for gastrointestinal screening at a leading hospital in Denmark. (GSS)

🪑 At 8 cents, this was still trading well below cash backing. 

I had a feeling it would jump on just any news, up 20% on open - I didn’t end up pulling the trigger on the trade, however.

ReNerve (ASX: RNV) has entered Stage 3 of scaled commercial production for its Nerve Guide Matrix, bringing it closer to an FDA submission by the end of 2026. (RNV)

Immutep (ASX: IMM) receives FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma. (IMM)

🪑 It will be interesting to see how the market values IMM’s pipeline of other efti alfa drugs after the failed futility analysis. 

I think it would be impossible to give any weight to these until after the company's root cause analysis results are available.

Mesoblast (ASX: MSB) secures exclusive rights to a CAR (chimeric antigen receptor) to enhance its stem cell product’s targeting of autoimmune and inflammatory diseases like Crohn's and Lupus. (MSB)

Lumos Diagnostics (ASX: LDX) expands the rollout of its FebriDx point-of-care diagnostics product with WellStreet, from a single site to 43 additional urgent care locations. (LDX)

Noxopharm (ASX: NOX) promotes Dr Oliver Laczka to CEO (former CSO). (NOX)

Interim results from AVITA Medical’s (ASX: AVH) Cohealyx skin graft product show a 20-day reduction in skin graft time from current benchmarks. (AVH)

🪑 AVH’s Cohealyx product is in the market. But studies like these are very important for surgeons' adoption. 

Importantly, there was high ‘investigator satisfaction’ (representing the people who would potentially use and buy the product).

Telix Pharmaceuticals (ASX: TLX) issued US$600M in convertible bonds at 1.50% annual interest, upsizing from US$550M due to strong demand. 37.5% conversion premium. (TLX)

🪑 Key point here is that the deal was ‘upsized’, showcasing the institutional interest in the Telix story.

Percheron Therapeutics (ASX: PER) successfully raised $2.2M through a 2-for-5 entitlement. (PER)

🪑 I took a small stab at this raise as a trade.

AbbVie licenses a pain treatment from China’s Haisco Pharmaceutical Group for up to US$715M. (BioSpace)

🪑 No pain. No gain.